Cancer Research

Cancer is a term used to define a group of diseases in which abnormal cells divide without control, are able to invade neighboring tissues/organs and metastasize. Cancer has been characterized by six hallmarks; self sufficiency in proliferative growth signals, insensitivity to growth inhibitors, evasion of apoptosis, limitless replicative potential, ability to develop blood vessels (angiogenesis), and tissue invasion and metastasis.

Cancer Research Products Areas

Products for Cancer Research - Page 116

  1. Cat.No. Product Name Information/Activity
  2. BCC7982 CEP 1347 156177-65-0 CEP 1347 chemical structure
  3. BCC8093 IQ 3 312538-03-7 IQ 3 chemical structure
  4. BCC5777 JIP-1 (153-163) 438567-88-5 JIP-1 (153-163) chemical structure
  5. BCC2474 SP 600125 JNK inhibitor; prevents BMP9-induced osteogenic differentiation of MSCs,SP600125 is a broad-spectrum JNK inhibitor for JNK1, JNK2 and JNK3 with IC50 of 40 nM, 40 nM and 90 nM in cell-free assays, respectively; 10-fold greater selectivity against MKK4, 25-fold greater selectivity against MKK3, MKK6, PKB, and PKCα, and 100-fold selectivity against ERK2, p38, Chk1, EGFR etc. SP 600125 chemical structure
  6. BCC7999 SR 3576 1164153-22-3 SR 3576 chemical structure
  7. BCC7725 SU 3327 SU3327 is a potent, selective and substrate-competitive JNK inhibitor with an IC50 of 0.7 μM. SU3327 also inhibits protein-protein interactions between JNK and JNK Interacting Protein (JIP) with an IC50 of 239 nM. SU3327 shows less active against p38α and Akt kinase. SU 3327 chemical structure
  8. BCC5148 TCS JNK 5a TCS JNK 5a is a potent JNK3 inhibitor with a pIC50 of 6.7. TCS JNK 5a also inhibits JNK2 with a pIC50 of 6.5. TCS JNK 5a chemical structure
  9. BCC7607 TCS JNK 6o JNK Inhibitor VIII (TCS JNK 6o) is a c-Jun N-terminal kinases (JNK-1, -2, and -3) inhibitor with Ki values of 2 nM, 4 nM, 52 nM, respectively, and has IC50 values of 45 nM and 160 nM for JNK-1 and -2, respectively. TCS JNK 6o chemical structure
  10. BCC8037 AL 8697 AL 8697, a specific and orally active p38α MAPK inhibitor with an IC50 of 6 nM, 14-fold less potent in p38β MAPK (IC50=82 nM), exhibits anti-inflammatory activity. AL 8697 chemical structure
  11. BCC6084 AMG 548 AMG-548, an orally active and selective p38α inhibitor (Ki=0.5 nM), shows slightly selective over p38β (Ki=36 nM) and >1000 fold selective against p38γ and p38δ. AMG 548 is also extremely potent in the inhibition of whole blood LPS stimulated TNFα (IC50=3 nM). AMG-548 inhibits Wnt signaling by directly inhibiting Casein kinase 1 isoforms δ and ε. AMG 548 chemical structure

Items 1151 to 1160 of 1172 total